The 6 analysts offering 12-month price forecasts for ADC Therapeutics SA have a median target of 44.00, with a high estimate of 55.00 and a low estimate of 33.00. The median estimate represents a +69.10% increase from the last price of 26.02.
The current consensus among 7 polled investment analysts is to Buy stock in ADC Therapeutics SA. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.92
Reporting Date Nov 18
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.